Published in J Exp Med on November 01, 1981
Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med (1985) 3.56
Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies. J Exp Med (1983) 1.79
In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor. Proc Natl Acad Sci U S A (1983) 1.52
Encephalitogenic T cell clones specific for myelin basic protein. An unusual bias in antigen recognition. J Exp Med (1985) 1.46
Prevention of diabetes in nonobese diabetic mice by anti-I-A monoclonal antibodies: transfer of protection by splenic T cells. Proc Natl Acad Sci U S A (1988) 1.26
Monoclonal anti-I-A antibody reverses chronic paralysis and demyelination in Theiler's virus-infected mice: critical importance of timing of treatment. J Virol (1987) 1.21
Conversion of immunity to suppression by in vivo administration of I-A subregion-specific antibodies. J Exp Med (1982) 1.19
In vivo prevention of thyroid and pancreatic autoimmunity in the BB rat by antibody to class II major histocompatibility complex gene products. Proc Natl Acad Sci U S A (1985) 1.04
I-J-restricted interactions in the generation of azobenzenearsonate-specific suppressor T cells. J Exp Med (1982) 0.99
Disappearance and reappearance of B cells after in vivo treatment with monoclonal anti-I-A antibodies. Proc Natl Acad Sci U S A (1984) 0.96
Monoclonal anti-Ia antibodies suppress the flare up reaction of antigen induced arthritis in mice. Clin Exp Immunol (1986) 0.91
The interaction of interdigitating cells and lymphocytes in vitro and in vivo. Immunology (1988) 0.82
Anti-class II MHC antibodies prevent and treat EAE without APC depletion. Immunology (1994) 0.75
Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and Ia antigens. Curr Top Microbiol Immunol (1978) 13.40
Studies on the chemical basis of the antigenicity of proteins. 5. Synthesis, characterization and immunogenicity of some multichain and linear polypeptides containing tyrosine. Biochem J (1962) 4.82
The major histocompatibility complex of the mouse. Science (1979) 4.76
Genetic control of the immune response. Mapping of the Ir-1 locus. J Exp Med (1972) 3.96
Genetic control of specific immune suppression. II. H-2-linked dominant genetic control of immune suppression by the random copolymer L-glutamic acid50-L-tyrosine50 (GT). J Exp Med (1975) 3.17
T lymphocyte-enriched murine peritoneal exudate cells. III. Inhibition of antigen-induced T lymphocyte Proliferation with anti-Ia antisera. J Immunol (1976) 2.64
Genetic control of the immune response. A selective defect in immunologic (IgG) memory in nonresponder mice. J Exp Med (1972) 2.60
Different macrophage populations distinguished by means of fluorescent polysaccharides. Recognition and properties of marginal-zone macrophages. Eur J Immunol (1981) 2.47
Organization of the immune response genes. Science (1979) 2.18
Reduction of syngeneic tumor growth by an anti-I-J-alloantiserum. Proc Natl Acad Sci U S A (1977) 1.93
Inhibition of immune responses in vitro by specific antiserums to Ia antigens. Science (1975) 1.65
Effects of blocking helper T cell induction in vivo with anti-Ia antibodies. Possible role of I-A/E hybrid molecules as restriction elements. J Exp Med (1980) 1.59
Alloantiserum-induced inhibition of immune response gene product function. II. Genetic analysis of target antigens. J Exp Med (1974) 1.45
Potentiation of a primary in vivo antibody response by alloantisera against gene products of the I region of the H-2 complex. Proc Natl Acad Sci U S A (1977) 1.36
A cardinal role for I-region antigens (Ia) in immunological enhancement, and the clinical implications. Transplant Rev (1976) 1.35
The association between genes in the major histocompatibility complex and disease susceptibility,. Annu Rev Med (1977) 1.33
Modulation of Schistosoma mansoni egg-induced granuloma formation: I-J restriction of T cell-mediated suppression in a chronic parasitic infection. Proc Natl Acad Sci U S A (1981) 1.27
Major histocompatibility complex-restricted self recognition. A monoclonal anti-I-Ak reagent blocks helper T cell recognition of self major histocompatibility complex determinants. J Exp Med (1980) 1.14
In vivo or in vitro treatments with anti-I-J alloantisera abolish immunity to AKR leukemia. Proc Natl Acad Sci U S A (1980) 1.13
Mechanisms of regulation of cell-mediated immunity: anti-I-A alloantisera interfere with induction and expression of T-cell-mediated immunity to cell-bound antigen in vivo. Clin Immunol Immunopathol (1980) 1.10
Participation of suppressor T cells in the immunosuppressive activity of a heteroantiserum to human Ia-like antigens (p23,30). J Exp Med (1980) 1.09
Definitive mapping of the immune response gene(s) for (T,G)-A--L to the I-A subregion. J Immunol (1980) 0.92
Antigen specific T cell factors in the genetic control of the immune response to poly(tyr,glu)poly(pro)--poly(lys). Adv Exp Med Biol (1976) 0.80
Histocompatibility-linked immune response genes. Science (1972) 16.79
HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature (1987) 10.70
Genetic control of specific immune responses. Adv Immunol (1969) 8.81
Genetic control of the antibody response. I. Demonstration of determinant-specific differences in response to synthetic polypeptide antigens in two strains of inbred mice. J Exp Med (1965) 7.27
Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A (1997) 6.99
A new I subregion (I-J) marked by a locus (Ia-4) controlling surface determinants on suppressor T lymphocytes. J Exp Med (1976) 6.11
Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell (1988) 5.73
HL-A, immune-response genes, and disease. Lancet (1974) 5.67
Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today (1995) 5.32
Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature (1993) 5.10
Two-gene control of the expression of a murine Ia antigen. J Exp Med (1978) 4.79
Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol (2000) 4.70
Genetic control of the antibody response: relationship between immune response and histocompatibility (H-2) type. Science (1969) 4.53
Genetic control of the immune response. Mapping of the Ir-1 locus. J Exp Med (1972) 3.96
Genetic control of the antibody response in inbred mice. Transfer of response by spleen cells and linkage to the major histocompatibility (H-2) locus. J Exp Med (1968) 3.52
Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature (1988) 3.46
A sensitive radioimmunoassay for detecting products translated from cloned DNA fragments. Cell (1978) 3.30
The localization of antigen in relation to specific antibody-producing cells. I. Use of a synthetic polypeptide [(T,G)-A--L] labelled with iodine-125. Immunology (1966) 3.09
Analysis of HLA-D region-associated molecules with monoclonal antibody. Proc Natl Acad Sci U S A (1979) 3.06
Genetic control of the immune response. The effect of thymectomy on the primary and secondary antibody response of mice to poly-L(tyr, glu)-poly-D, L-ala--poly-L-lys. J Exp Med (1972) 3.06
CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J Immunol (1996) 3.02
Selective expression of H-2 (i-region) loci controlling determinants on helper and suppressor T lymphocytes. J Exp Med (1976) 2.94
In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med (1987) 2.93
Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A (1990) 2.88
The murine E alpha immune response gene. Cell (1983) 2.86
Detection of a common polypeptide chain in I--A and I--E sub-region immunoprecipitates. Mol Immunol (1979) 2.86
Endotoxin-induced uveitis in rats as a model for human disease. Nature (1980) 2.85
Several mechanisms can account for defective E alpha gene expression in different mouse haplotypes. Proc Natl Acad Sci U S A (1983) 2.84
Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell (1989) 2.77
The first external domain of the nonobese diabetic mouse class II I-A beta chain is unique. Proc Natl Acad Sci U S A (1987) 2.77
Histocompatibility (HL-A) antigens associated with systemic lupus erythematosus. A possible genetic predisposition to disease. N Engl J Med (1971) 2.69
Correlation of grain counts with radioactivity (125I and tritium) in autoradiography. Exp Cell Res (1966) 2.62
Protein clinical manifestations of primary tumors of the heart. Am J Med (1972) 2.61
Regions of allelic hypervariability in the murine A alpha immune response gene. Cell (1983) 2.53
Genetic control of the antibody response. II. Further analysis of the specificity of determinant-specific control, and genetic analysis of the response to (H,G)-A--L in CBA and C57 mice. J Exp Med (1967) 2.41
Histocompatibility-linked genetic control of disease susceptibility. Murine lymphocytic choriomeningitis virus infection. J Exp Med (1973) 2.39
Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med (1994) 2.33
A sequential model for peptide binding and transport by the transporters associated with antigen processing. Immunity (1994) 2.26
Autoimmune diseases: the failure of self tolerance. Science (1990) 2.24
Local proliferation of fibroblast-like synoviocytes contributes to synovial hyperplasia. Results of proliferating cell nuclear antigen/cyclin, c-myc, and nucleolar organizer region staining. Arthritis Rheum (1994) 2.19
Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: a family study. Proc Natl Acad Sci U S A (1988) 2.19
Genetic and functional analysis of the Ia antigens: their possible role in regulating the immune response. Transplant Rev (1976) 2.15
Genetic control of the antibody response to poly-L(Tyr,Glu)-poly-D,L-Ala--poly-L-Lys in C3H--CWB tetraparental mice. J Exp Med (1974) 2.14
Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci U S A (1990) 2.13
Variable synthesis and expression of E alpha and Ae (E beta) Ia polypeptide chains in mice of different H-2 haplotypes. Immunogenetics (1981) 2.13
A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity (1994) 2.09
Fibroproliferation and mast cells in the acute respiratory distress syndrome. Thorax (1998) 2.08
The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity (1996) 2.05
T cell recognition as the target for immune intervention in autoimmune disease. Cell (1989) 2.04
In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc Natl Acad Sci U S A (1981) 2.00
Increased frequency of HLA-Cw3 and HLA-Dw4 in rheumatoid arthritis. Arthritis Rheum (1977) 1.95
Genetic control of the antibody response. 3. Qualitative and quantitative characterization of the antibody response to (T,G)-A--L in CBA and C57 mice. J Immunol (1968) 1.94
Insulin-dependent diabetes mellitus: the initial lesion. N Engl J Med (1981) 1.93
Allelic variation in the DR subregion of the human major histocompatibility complex. Proc Natl Acad Sci U S A (1987) 1.92
Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med (1997) 1.92
Predominant expression of a T cell receptor V beta gene subfamily in autoimmune encephalomyelitis. J Exp Med (1988) 1.89
Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis. Proc Natl Acad Sci U S A (1996) 1.85
Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum (2001) 1.85
Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies. J Exp Med (1983) 1.79
CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol (1997) 1.79
The nature of the antigenic determinant in a genetic control of the antibody response. J Exp Med (1969) 1.74
Characterization of HLA-D-region antigens by two-dimensional gel electrophoresis. Molecular-genotyping. J Exp Med (1980) 1.73
Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotoxin-beta receptor-IgG1 fusion protein. Proc Natl Acad Sci U S A (1996) 1.71
The murine Ia alpha chains, E alpha and A alpha, show a surprising degree of sequence homology. Proc Natl Acad Sci U S A (1983) 1.69
Gene conversion between murine class II major histocompatibility complex loci. Functional and molecular evidence from the bm 12 mutant. J Exp Med (1984) 1.66
Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid dependent optic neuritis not associated with demyelinating disease. Br J Ophthalmol (2004) 1.66
Mapping of the class II region of the human major histocompatibility complex by pulsed-field gel electrophoresis. Nature (1986) 1.64
Prevalence of serologic evidence of cat scratch disease in patients with neuroretinitis. Ophthalmology (2000) 1.62
Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol (1995) 1.59
The genetic control of antibody specificity. J Exp Med (1969) 1.58
Structure of murine Ia antigens: partial NH2-terminal amino acid sequences of products of the I-E or I-C subregion. Proc Natl Acad Sci U S A (1977) 1.56
Genetic control of the immune response. Frequency and characteristics of antigen-binding cells in high and low responder mice. J Exp Med (1973) 1.55
Isolation and characterization of a cDNA clone for the murine I-E beta polypeptide chain. Proc Natl Acad Sci U S A (1983) 1.54
Genetic control of radiation leukemia virus-induced tumorigenesis. I. Role of the major murine histocompatibility complex, H-2. J Exp Med (1977) 1.54
Increased synthesis and expression of H-2 antigens on thymocytes as a result of radiation leukemia virus infection: a possible mechanism for H-2 linked control of virus-induced neoplasia. J Exp Med (1978) 1.53
In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor. Proc Natl Acad Sci U S A (1983) 1.52
Regulation of the immune response by the major histocompatibility system. N Engl J Med (1980) 1.52
Involvement of distinct murine T-cell receptors in the autoimmune encephalitogenic response to nested epitopes of myelin basic protein. Proc Natl Acad Sci U S A (1988) 1.51
Genetic control of the immune response: in vitro stimulation of lymphocytes by (T,G)-A--L, (H,G)-A--L, and (Phe,G)-A--L. J Exp Med (1974) 1.50
A suppressor T cell of the mixed lymphocyte reaction in man specific for the stimulating alloantigen. Evidence that identity at HLA-D between suppressor and responder is required for suppression. J Exp Med (1978) 1.49
Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes (1998) 1.47
Genetics and expression of mouse Ia antigens. Annu Rev Immunol (1985) 1.45
A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (1991) 1.45
Systemic sulfonamides as a cause of bilateral, anterior uveitis. Arch Ophthalmol (1991) 1.42
Treatment of NZB/NZW F1 hybrid mice with Mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune disease. Arthritis Rheum (1981) 1.41
Sequence analysis and structure-function correlations of murine q, k, u, s, and f haplotype I-A beta cDNA clones. Proc Natl Acad Sci U S A (1986) 1.39
DNA sequence and characterization of human class II major histocompatibility complex beta chains from the DR1 haplotype. Proc Natl Acad Sci U S A (1985) 1.39
The Fc receptor on thymus-derived lymphocytes. IV. Inhibition of binding of antigen-antibody complexes to Fc receptor-positive T cells by anti-Ia sera. J Exp Med (1977) 1.39
Essential laboratory tests in uveitis. Dev Ophthalmol (1999) 1.38
Histocompatibility-linked genetic control of specific immune responses to viral infection. Transplant Rev (1974) 1.37
Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci (1994) 1.34
Ocular syphilis in patients with human immunodeficiency virus infection. Am J Ophthalmol (1988) 1.33
The association between genes in the major histocompatibility complex and disease susceptibility,. Annu Rev Med (1977) 1.33
Genetic control of the immune response to (T,G)-A--L in C3H in equilibrium C57 tetraparental mice. Cell Immunol (1974) 1.32
Structure and polymorphism of murine and human class II major histocompatibility antigens. Immunol Rev (1985) 1.32
Antigen binding T and B lymphocytes. I. Differences in cellular specificity and influence of metabolic activity on interaction of antigen with T and B cells. J Immunol (1974) 1.32